bluebird bio (BLUE) – Hot Upgrades
-
BofA Securities Upgrades bluebird bio (BLUE) to Buy, 'positioned to lead in attractive sickle cell gene therapy market'
-
Barclays Upgrades bluebird bio (BLUE) to Overweight
-
-
-
-
-
-
-
-
-
-
-
-
Back to BLUE Stock Lookup